Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials

Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials

Taro Kishi,1 Kazuto Oya,1 Yuki Matsui,1,2 Ikuo Nomura,1 Kenji Sakuma,1 Makoto Okuya,1 Yuki Matsuda,3 ,Kiyoshi Fujita,4 Toshihiko Funahashi,2 Reiji Yoshimura,5 Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan; 2Department of Psychiat...

Full description

Bibliographic Details
Main Authors: Kishi T, Oya K, Matsui Y, Nomura I, Sakuma K, Okuya M, Matsuda Y, Fujita K, Funahashi T, Yoshimura R, Iwata N
Format: Article
Language:English
Published: Dove Medical Press 2018-10-01
Series:Neuropsychiatric Disease and Treatment
Subjects:
schizophrenia
brexpiprazole 2mg/day
brexpiprazole 4mg/day
efficacy
safety
systematic review and meta-analysis
Online Access:https://www.dovepress.com/comparison-of-the-efficacy-and-safety-of-4-and-2-mgday-brexpiprazole-f-peer-reviewed-article-NDT

Internet

https://www.dovepress.com/comparison-of-the-efficacy-and-safety-of-4-and-2-mgday-brexpiprazole-f-peer-reviewed-article-NDT

Similar Items